↓ Skip to main content

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Overview of attention for article published in Neuro-Oncology, April 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 2,759)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

blogs
1 blog
twitter
111 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Published in
Neuro-Oncology, April 2020
DOI 10.1093/neuonc/noaa107
Pubmed ID
Authors

Carmen Balana, Maria Angeles Vaz, Juan Manuel Sepúlveda, Carlos Mesia, Sonia del Barco, Estela Pineda, Jose Muñoz-Langa, Anna Estival, Ramón de las Peñas, Jose Fuster, Regina Gironés, Luis Miguel Navarro, Miguel Gil-Gil, Miriam Alonso, Ana Herrero, Sergio Peralta, Clara Olier, Pedro Perez-Segura, Maria Covela, Maria Martinez-García, Alfonso Berrocal, Oscar Gallego, Raquel Luque, Franciso Javier Perez-Martín, Anna Esteve, Nuria Munne, Marta Domenech, Salvador Villa, Carolina Sanz, Cristina Carrato

Twitter Demographics

The data shown below were collected from the profiles of 111 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 17%
Student > Postgraduate 3 13%
Student > Doctoral Student 3 13%
Professor > Associate Professor 3 13%
Researcher 2 8%
Other 3 13%
Unknown 6 25%
Readers by discipline Count As %
Medicine and Dentistry 14 58%
Biochemistry, Genetics and Molecular Biology 2 8%
Veterinary Science and Veterinary Medicine 1 4%
Unknown 7 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 81. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2021.
All research outputs
#325,243
of 17,977,824 outputs
Outputs from Neuro-Oncology
#30
of 2,759 outputs
Outputs of similar age
#11,227
of 285,939 outputs
Outputs of similar age from Neuro-Oncology
#2
of 57 outputs
Altmetric has tracked 17,977,824 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,759 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,939 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.